SCHEMBL373400

SCHEMBL373400

c1ccc2oc(C3CCNCC3)nc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 1/20 0.54
LMNA P02545 6/20 0.53
BCHE P06276 1/20 0.51
ACHE P22303 1/20 0.51
HTR2B P41595 1/20 0.49
THRB P10828 2/20 0.47
TP53 P04637 2/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
USP2 O75604 1/20 0.46
MAPT P10636 1/20 0.45
EPHX1 P07099 1/20 0.44
EPHX2 P34913 1/20 0.44
KCNH2 Q12809 1/20 0.44
CACNA1C Q13936 1/20 0.44
SCN5A Q14524 1/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29891587 0.94 LMNA (0.49) MPOLMNABCHEACHEHTR2B
SCHEMBL23411036 0.94 LMNA (0.49) MPOLMNABCHEACHEHTR2B
SCHEMBL26862272 0.88 LMNA (0.60) LMNAHTR2BTHRBTP53MEN1
SCHEMBL14895871 0.84 LMNA (0.57) LMNAHTR2BTHRBTP53MEN1
SCHEMBL4457699 0.84 RAB9A (0.59) LMNAHTR2BTHRBTP53MEN1
SCHEMBL2574181 0.83 LMNA (0.49) MPOLMNAHTR2BTHRBTP53
SCHEMBL1128181 0.83 RAB9A (0.62) LMNAHTR2BTHRBTP53MEN1
SCHEMBL1001293 0.81 MPO (0.56) MPOLMNAHTR2BTHRBTP53
SCHEMBL3120801 0.81 LMNA (0.55) LMNAHTR2BTHRBTP53MEN1
SCHEMBL7970307 0.80 LMNA (0.45) MPOLMNAHTR2BTHRBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2025-11-25 US disclosed
CN-119564686-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-03-07 CN disclosed
CN-119523983-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-28 CN disclosed
CN-119424429-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-14 CN disclosed
CN-115003665-B DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2024-11-08 CN disclosed
US-11998539-B2 Substituted aminoquinolones as DGKalpha inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-06-04 US disclosed
US-20230201186-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-29 US disclosed
US-20230148194-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-05-11 US disclosed
EP-4065574-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2022-10-05 EP disclosed
CN-115003665-A Substituted aminoquinolones as immunoactive DGK alpha inhibitors 拜耳公司 2022-09-02 CN disclosed
WO-2000056712-A1 SULFONAMIDE DERIVATIVES AS 5-HT7 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2000-09-28 WO disclosed
US-6037342-A BENZOXAZOLE DERIVATIVES HAVING STRONG SEROTONIN 5-HT.SUB.3 RECEPTOR ANTAGONISM; TREATING FUNCTIONAL DISORDERS OF DIGESTIVE ORGANS MEIJI SEIKA KAISHA, LTD (JP) 2000-03-14 US disclosed
US-5998412-A ANTIARTHRITIC AGENTS; OSTEOPOROSIS SYNTEX (U.S.A.) INC. (US) 1999-12-07 US disclosed
EP-0958287-A1 SULFAMIDE-METALLOPROTEASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 1999-11-24 EP disclosed
US-5968923-A ANTIINFLAMMATORY AGENTS, TREATMENT OF NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS PFIZER INC. (US) 1999-10-19 US disclosed
US-5849765-A Tetrahydropyridine derivatives as dopamine receptor subtype ligands MERCK SHARP & DOHME, LTD. (GB) 1998-12-15 US disclosed
WO-1998032748-A1 SULFAMIDE-METALLOPROTEASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 1998-07-30 WO disclosed
EP-0806419-A1 Benzoxazole derivatives as serotonin 5-HT3 receptor partial activator MEIJI SEIKA KAISHA LTD. (JP) 1997-11-12 EP disclosed
CN-1154699-A (Azetidin-1-ylalkyl) lactams as tachykinin antagonists PFIZER LTD (IE) 1997-07-16 CN disclosed
US-4127579-A HYPOTENSIVE E. R. SQUIBB & SONS, INC. (US) 1978-11-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230148194-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION DGKK, DGKG, DGKA MPO 2974/4885LMNA 1953/4885BCHE 2188/4885
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DGKK, DGKG, DGKA MPO 2974/4885LMNA 1953/4885BCHE 2188/4885
US-11998539-B2 Substituted aminoquinolones as DGKalpha inhibitors for immune activation DGKK, DGKG, DGKA MPO 2974/4885LMNA 1953/4885BCHE 2188/4885
US-20230201186-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION DGKK, DGKG, DGKA MPO 2974/4885LMNA 1953/4885BCHE 2188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.